Karl L. Mettinger

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.

American Society of Hematology provides the most current practice tools, clinical support and educational products needed in hematology. The firm offers educational products and services for clinicians and scientists. The company is headquartered in Washington, DC.

American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA.

The American company was founded by Karl L. Mettinger and Kent Persson, with Karl L. Mettinger serving as CEO since incorporation.

IVAX LLC discovers, develops, manufactures, and markets generic pharmaceuticals, respiratory drugs, and cancer treatments. It offers drugs for the treatment of multiple sclerosis, brain cancer, asthma, and epilepsy. The company was founded by Phillip Frost and Jane H. Hsiao in 1987 and is headquartered in Weston, FL.

SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA.